Newsbot

Is Hims & Hers Health (HIMS) A Bargain After Its Lilly Deal?

Eli Lilly’s new agreement with Hims & Hers Health (HIMS) puts Lilly’s obesity drugs Zepbound and Foundayo directly inside the telehealth platform, giving users streamlined access to FDA-approved GLP-1 treatments for weight loss.The Lilly partnership landed after a choppy stretch for Hims & Hers Health, with the share price jumping 8.06% over the past day but still down 11.98% over 30 days and 22.18% year to date. The three year total shareholder return of about 2.8x highlights the strength...

AI Slump Revives Asia’s Forgotten Trades From China to India

The unraveling of the AI trade after the US midterm elections is forcing investors to rethink their Asia playbook, reviving demand for out-of-favor Chinese and Indian stocks as well as companies poised to benefit from easing inflation and trade tensions.

AIM weekly movers: Allergy Therapeutics plans to leave AIM

Lower emissions fuel developer Quadrise (LON: QED) expects Valkor Technologies to pay $300,000 of the licence fee it owes in early November and the remaining $650,000 could be paid before the end of the year. This cash was expected in October. This is based on Valkor completing its fundraising. Shipment of the Multifuel Manufacturing unit […]The post AIM weekly movers: Allergy Therapeutics plans to leave AIM appeared first on UK Investor Magazine.

Aquis weekly movers: Stack BTC revises acquisition terms

Energy B (LON: NGRB) chairman David Lenigas bought 100,000 shares at 16p each and 50,000 shares at 25p each. Silvertree Partners will take over accounting and company secretary activities for the company. The share price jumped 79.8% to 29p. Astrid Intelligence (LON: ASTR), which is focused on the Bittensor decentralised AI ecosystem, says Zils will operate […]The post Aquis weekly movers: Stack BTC revises acquisition terms appeared first on UK Investor Magazine.

Claude Deleted a Law Professor’s Notes; Dropbox Had Copies

95,000+ executives read Business Engineer for the AI strategy frameworks cited by ChatGPT, Claude, and Perplexity. A note on sourcing. The account of the deletion is William Baude’s, from an X post and screenshot of 5 November 2026, with his replies as quoted by Dexerto. We did not see the files or the full session. […]

Hims & Hers Health (HIMS) Could Be 85% Undervalued Following The Eli Lilly Deal

Hims & Hers Health (HIMS) just signed a new agreement with Eli Lilly that allows its users to access branded obesity drugs Zepbound and Foundayo directly through the telehealth platform, including integrated consultations and home delivery. Investor reaction has been mixed in the run up to this Eli Lilly deal, with the 1 day share price return of 8.06% contrasting with a 30 day share price return down 11.98% and a year to date share price return down 22.18%. Capitalize on the renewed focus...

Hims Partnership Could Be A Big Deal For Eli Lilly (LLY)

Eli Lilly and Hims & Hers Health announced a partnership in early November 2026 that lets eligible patients obtain Zepbound and Foundayo on the Hims & Hers telehealth platform at Lilly’s self pay prices, with prescriptions written by independent clinicians and medicines shipped directly to patients’ homes.The move extends Eli Lilly’s obesity portfolio into a large consumer digital channel at the same time the company has lifted 2026 revenue guidance to US$91b to US$92b. This ties demand for...